Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial

Fineline Cube Mar 31, 2026
Company Drug

Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels

Fineline Cube Mar 31, 2026
Company Medical Device

Peijia Medical Enrolls First Patient in HighLife TSMVR Study

Fineline Cube Nov 14, 2022

China’s Peijia Medical Limited (HKG: 9996) has announced the enrollment of the first patient and...

Company Medical Device

Acotec Scientific Secures FDA 510(k) Approval for Vericor Catheter

Fineline Cube Nov 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received a 510(k)...

Company

CStone Pharmaceuticals Suspends Operations at Suzhou Plant to Cut Costs

Fineline Cube Nov 14, 2022

CStone Pharmaceuticals (HKG: 2616) has decided to suspend manufacturing operations at its Suzhou industrialization plant,...

Company Deals

Daxiang Biotech Raises RMB 100M in Pre-Series B Financing for Organoid-on-a-Chip

Fineline Cube Nov 14, 2022

Beijing-based Daxiang Biotech Co., Ltd., a leading domestic company in the organoid-on-a-chip field, has reportedly...

Company

Harbin Gloria Pharmaceuticals Faces Change in Control Amid Bankruptcy

Fineline Cube Nov 14, 2022

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has disclosed that its controlling shareholder, Harbin...

Company Deals

HitGen Partners with Daewoong Pharmaceutical for Drug Discovery

Fineline Cube Nov 14, 2022

China-based HitGen Inc. (SHA: 688222) has announced a research collaboration agreement with South Korea’s Daewoong...

Deals

AstraZeneca and CICC Capital Launch RMB 3 Billion Fund in Hangzhou

Fineline Cube Nov 14, 2022

The joint venture (JV) between UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CICC...

Company Drug

Henlius Biotech’s BRAF V600E Inhibitor HLX208 Approved for Clinical Study in China

Fineline Cube Nov 14, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

China Updates Hypertension Guidelines, Lowers Diagnostic Threshold

Fineline Cube Nov 14, 2022

The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations...

Company

AstraZeneca Reports 19% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 11, 2022

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) released its Q3 2022 earnings report, showing...

Company Drug

FDA Approves Phase Ib Study for Jiangsu Yahong’s APL1401 in Ulcerative Colitis

Fineline Cube Nov 11, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...

Company Deals

Baheal Partners with AstraZeneca for Commercial Rights to Onglyza

Fineline Cube Nov 11, 2022

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca...

Company

EQRx Shifts Strategy Amid FDA Feedback on China-Sourced Data

Fineline Cube Nov 11, 2022

US-based EQRx Inc. (Nasdaq: EQRX), a biopharma originally established with the aim of “radically” disrupting...

R&D

Peking University Study Identifies Liver Cancer Immune Microenvironment Subtypes

Fineline Cube Nov 11, 2022

Researchers at Peking University have uncovered several subtypes in the tumor immune microenvironment (TIME) relevant...

Company Drug

CDE Prioritizes Review for Jiedi Pharma’s Mitotane and Other Key Drugs

Fineline Cube Nov 11, 2022

The Center for Drug Evaluation (CDE) website indicates that market filings for several key drugs,...

Company Drug

CanSino Biologics’ Inhalable COVID-19 Vaccine Authorized in Morocco

Fineline Cube Nov 11, 2022

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...

Company Drug

Luye Pharma’s Biosimilar LY06006/BA6101 Approved for Osteoporosis Treatment

Fineline Cube Nov 11, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...

Company Drug

Lundbeck’s Eptinezumab Launches in Boao Lecheng for Migraine Treatment

Fineline Cube Nov 11, 2022

Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone,...

Company Deals Digital

Novartis Partners with Alibaba Health to Enhance Patient Medication Accessibility

Fineline Cube Nov 11, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss...

Company Drug

RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis

Fineline Cube Nov 11, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...

Posts pagination

1 … 579 580 581 … 644

Recent updates

  • Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial
  • Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels
  • Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership
  • AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
  • Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial

Company Drug

Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.